According to information shared through ScienceDaily, the analysis revealed both well-known and lesser-discussed side effects associated with GLP-1 medications
In the trial, oral semaglutide appeared to have a safe and well-tolerated profile in line with previous oral semaglutide trials
In clinical trials, a consistent finding was that participants with sIBM, sarcopenia, or obesity with type 2 diabetes lost 47% (lean mass), while fat mass in obese patients without diabetes decreased from 1021 %
The FDA-approved injection sites for tirzepatide include the abdomen (excluding a 2-inch radius around the navel), thigh (front and outer aspects of the upper leg), and upper arm (back of the arm, in the fatty area)
When initiating tirzepatide, patients taking insulin or insulin secretagogues (such as sulfonylureas) should be advised about the increased risk of hypoglycemia, and dose reductions of these medications may be necessary
The overall trend is what matters most
